• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Eli Lilly touts data for concentrated insulin delivered via Insulet’s Omnipod tech

June 27, 2018 By Sarah Faulkner

Eli LillyEli Lilly (NYSE:LLY) touted data this week from a Phase III study evaluating its Humulin R U-500 concentrated insulin delivered via Insulet‘s (NSDQ:PODD) investigational Omnipod U-500 device.

The company reported that people with Type II diabetes taking Humulin R U-500 using the Omnipod device experienced greater A1c reductions and needed less daily insulin compared to adults using multiple daily injections to deliver high doses of insulin.

Eli Lilly, which presented these data at the annual meeting of the American Diabetes Association, developed its Humulin R U-500 product for people with diabetes who are insulin-resistant and need daily doses of more than 200 units of insulin.

“Concentrated insulins are effective treatment options for people with diabetes who have high insulin requirements,” Tom Hardy, senior medical director at Lilly, said in prepared remarks. “People who prefer to use an insulin pump currently do not have an option specifically for Humulin R U-500, which is five-times concentrated. These data show that Humulin R U-500 delivered with this investigational pump may help people better manage their blood sugar levels.”

The company noted that there was no significant difference in symptomatic or severe hypoglycemia between those in the pump group and those using multiple daily injections. Also, researchers observed higher rates of nocturnal hypoglycemia with the Omnipod-Humulin combination compared to multiple daily injections.

“These results show that Humulin R U-500 using Insulet Corporation’s Omnipod technology may help make it easier for people to titrate to their individual needs and improve their blood glucose control,” Dr. Trang Ly, Insulet’s SVP & medical director, added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Eli Lilly & Co., Insulet

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Reader Interactions

Comments

  1. deborah Schultz says

    July 3, 2018 at 9:27 am

    Please consider me for any type ll research. The pens hurt and leave lumps under my skin. I just hate them. I inject Levemir and Novo log-R. If 65 million people have this disease we need a better med.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS